» Articles » PMID: 33374213

Repurposing Clinical Agents for Chemical Exchange Saturation Transfer Magnetic Resonance Imaging: Current Status and Future Perspectives

Overview
Publisher MDPI
Specialty Chemistry
Date 2020 Dec 30
PMID 33374213
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Molecular imaging is becoming an indispensable tool to pursue precision medicine. However, quickly translating newly developed magnetic resonance imaging (MRI) agents into clinical use remains a formidable challenge. Recently, Chemical Exchange Saturation Transfer (CEST) MRI is emerging as an attractive approach with the capability of directly using low concentration, exchangeable protons-containing agents for generating quantitative MRI contrast. The ability to utilize diamagnetic compounds has been extensively exploited to detect many clinical compounds, such as FDA approved drugs, X-ray/CT contrast agents, nutrients, supplements, and biopolymers. The ability to directly off-label use clinical compounds permits CEST MRI to be rapidly translated to clinical settings. In this review, the current status of CEST MRI based on clinically available compounds will be briefly introduced. The advancements and limitations of these studies are reviewed in the context of their pre-clinical or clinical applications. Finally, future directions will be briefly discussed.

Citing Articles

Design Chemical Exchange Saturation Transfer Contrast Agents and Nanocarriers for Imaging Proton Exchange .

Su H, Chan K ACS Nano. 2024; 18(50):33775-33791.

PMID: 39642940 PMC: 11656841. DOI: 10.1021/acsnano.4c05923.


Intramolecular Hydrogen Bonding Based CEST MRI Contrast Agents As an Emerging Design Strategy: A Mini-Review.

Mohanta Z, Gori S, McMahon M ACS Omega. 2024; 9(26):27755-27765.

PMID: 38973929 PMC: 11223143. DOI: 10.1021/acsomega.4c02296.


Metabolic brain imaging with glucosamine CEST MRI: in vivo characterization and first insights.

Rivlin M, Perlman O, Navon G Sci Rep. 2023; 13(1):22030.

PMID: 38086821 PMC: 10716494. DOI: 10.1038/s41598-023-48515-5.


Contrasting Properties of Polymeric Nanocarriers for MRI-Guided Drug Delivery.

Lopuszynska N, Weglarz W Nanomaterials (Basel). 2023; 13(15).

PMID: 37570481 PMC: 10420849. DOI: 10.3390/nano13152163.


Acyl Hydrazides and Acyl Hydrazones as High-Performance Chemical Exchange Saturation Transfer MRI Contrast Agents.

Bo S, Zhang D, Ma M, Mo X, Stabinska J, McMahon M Pharmaceuticals (Basel). 2023; 16(5).

PMID: 37242423 PMC: 10223748. DOI: 10.3390/ph16050639.


References
1.
Togao O, Keupp J, Hiwatashi A, Yamashita K, Kikuchi K, Yoneyama M . Amide proton transfer imaging of brain tumors using a self-corrected 3D fast spin-echo dixon method: Comparison With separate B correction. Magn Reson Med. 2016; 77(6):2272-2279. DOI: 10.1002/mrm.26322. View

2.
Stabinska J, Cronenberg T, Wittsack H, Lanzman R, Muller-Lutz A . Quantitative pulsed CEST-MRI at a clinical 3T MRI system. MAGMA. 2017; 30(5):505-516. DOI: 10.1007/s10334-017-0625-0. View

3.
Sinharay S, Howison C, Baker A, Pagel M . Detecting in vivo urokinase plasminogen activator activity with a catalyCEST MRI contrast agent. NMR Biomed. 2017; 30(7). PMC: 5704996. DOI: 10.1002/nbm.3721. View

4.
Nasrallah F, Pages G, Kuchel P, Golay X, Chuang K . Imaging brain deoxyglucose uptake and metabolism by glucoCEST MRI. J Cereb Blood Flow Metab. 2013; 33(8):1270-8. PMC: 3734779. DOI: 10.1038/jcbfm.2013.79. View

5.
Thoren L . The dextrans--clinical data. Dev Biol Stand. 1980; 48:157-67. View